Pluristem Therapeutics Inc. Stock price
Is Pluristem Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.
Key metrics
Pluristem Therapeutics Inc. Stock Analysis
Analyst Opinions
7 Analysts have issued a Pluristem Therapeutics Inc. forecast:
Analyst Opinions
7 Analysts have issued a Pluristem Therapeutics Inc. forecast:
Don't miss a Thing! We will send you all news about Pluristem Therapeutics Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Pluristem Therapeutics, Inc. engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. It focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
| Head office | United States |
| CEO | Mr. Yanay |
| Employees | 135 |
| Founded | 2001 |
| Website | pluri-biotech.com |


